Intranasal epinephrine was administered within 1 minute of identifying the reaction or when the patient returned to the ...

U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) ...

Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with ...

Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may ...

Ustekinumab had a market value of approximately $17.1 billion for the 12 months ending December 2024, per IQVIA.

Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may ...

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation to report results from real ...

Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.